

The Lancet publishes Phase III data of ZyCoV-D

- *The results of the Phase I part of the Phase I/II clinical trial have already been published in the EClinical Medicine Journal of The Lancet.*

Ahmedabad, 1 April, 2022

Zydus Lifesciences, a global discovery-driven lifesciences company announced that safety and efficacy analysis data from Phase III clinical trial of its Plasmid DNA COVID-19 vaccine ZyCoV-D has been peer reviewed and published in The Lancet, a reputed and well known medical journal.

The double blind, placebo controlled, randomised Phase III clinical trial of the world's first plasmid DNA vaccine, ZyCoV-D was one of the largest trials for a COVID-19 vaccine in India and was conducted on over 28000 healthy adult volunteers in over 50 sites across the country. The trial was carried out during the peak of the second wave of COVID-19 infection. The efficacy of the vaccine stood at 66.6% at a time when Delta Variant of the SARS COV-2 virus was the prevalent strain across India.

ZyCoV-D is a three dose intradermal vaccine administered using a needle-free applicator. The plug-and-play technology of vaccine equips it to adapt to the rapidly mutating SARS COV-2 virus. The results of the Phase I part of the Phase I/II clinical trial have already been published in the EClinical Medicine Journal of The Lancet.

Speaking on the development, Dr. Sharvil Patel, Managing Director, Zydus Lifesciences Ltd said "We are pleased that the outcomes of the Phase III trial of ZyCoV-D have been peer reviewed and published in The Lancet. This attests to the compliance with the global best practices and stringent peer review parameters of clinical trials."

The peer reviewed article can be accessed using the following link:

[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(22\)00151-9/fulltext](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)00151-9/fulltext)

Facts about ZyCoV-D

- ZyCoV-D is an intradermal vaccine, administered in three doses.



**PRESS
RELEASE**

For further information please contact :
The Corporate Communications Department

Zydus Lifesciences Limited
(formerly known as Cadila Healthcare Limited)

Regd. Office : 'Zydus Corporate Park',
Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar),
Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad 382
481, Gujarat, India. | Phone : +91-79-71800000,
+91-79-48040000 | website : www.zyduslife.com
CIN : L24230GJ1995PLC025878



Dedicated To Life

- It is administered using The PharmaJet® needle free system, Tropis®, which leads to a significant reduction in local side effects.
- ZyCoV-D is stored at 2-8 degree C but has shown good stability at temperature of 25 degree C for at least three months. The thermostability of the vaccine will help in easy transportation and storage of the vaccine and reduce any cold chain breakdown challenges leading to vaccine wastage.
- The Plasmid DNA platform also allows generating new constructs quickly to deal with mutations in the virus, such as those already occurring.

About Zydus

The Zydus Group with an overarching purpose of empowering people with freedom to live healthier and more fulfilled lives, is an innovative, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs over 23000 people worldwide and is driven by its mission to unlock new possibilities in life-sciences through quality healthcare solutions that impact lives. The group aspires to transform lives through path-breaking discoveries. For more details visit www.zyduslife.com.



**PRESS
RELEASE**

For further information please contact :
The Corporate Communications Department

Zydus Lifesciences Limited
(formerly known as Cadila Healthcare Limited)

Regd. Office : 'Zydus Corporate Park',
Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar),
Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad 382
481, Gujarat, India. | Phone : +91-79-71800000,
+91-79-48040000 | website : www.zyduslife.com
CIN : L24230GJ1995PLC025878